Browse Items (18 total)

Tags: 2002, Adolescent, Child, Child Preschool, Davies P, Developmental Disabilities, Developmental Disabilities/complications, Developmental Medicine and Child Neurology, Dose-Response Relationship Drug, Epilepsy, Epilepsy/complications, Female, Humans, Infant, Lennox-Gastaut syndrome, Leukodystrophy, Male, Medical Records, melatonin, Melatonin/therapeutic use, MPSII, MPSIII, Nervous System Diseases, Nervous System Diseases/complications, Outpatients, pharmacologic intervention, Q3 Scoping Review Results, Ross C, Sex Factors, Sleep Disorders/complications/drug therapy, sleep disturbance/disorders, Sleep Wake Disorders, Vision Disorders, Vision Disorders/complications, Whitehouse W

Tags: 2012, Benke J R, Boss E F, characteristics, Cornelia de Lange syndrome, De Lange syndrome, insomnia, International Journal of Pediatric Otorhinolaryngology, Ishman S L, Kimball A, Kline A D, Levy H P, melatonin, Mettel T L, Otorhinolaryngology, Pediatrics, Rajan R, Sleep, sleep disturbance, sleep disturbance/disorders, Sleepiness, smith-magenis-syndrome, Trajectory

Tags: 2004, Antioxidants/therapeutic use, Appleton R E, Brain/physiopathology, Child, Developmental Disabilities/drug therapy/epidemiology/physiopathology, Developmental Medicine and Child Neurology, Humans, melatonin, Melatonin/therapeutic use, pharmacologic intervention, Phillips L, Rett syndrome, sleep disturbance/disorders, Sleep Wake Disorders/epidemiology, Wakefulness/physiology

Tags: 1999, Clarke A, Developmental Medicine and Child Neurology, Hancock E, Hunt A B A, melatonin, O'Callaghan F J K, Osborne J P, pharmacologic intervention, sleep disturbance/disorders, Tuberous Sclerosis

Tags: 2015, Actigraphy, autistic spectrum disorders, Bigger B, Canal M, characteristics, circadian rhythms, CONTROLLED-TRIAL, disturbance, Hare D J, Intellectual Disability, Jones S, Journal of Neurodevelopmental Disorders, Light, Mahon L V, melatonin, MPSIIIA, MPSIIIB, Mucopolysaccharidosis type III, Multiple disabilities, Mumford R A, Neurosciences & Neurology, Rare Disease, Sanfilippo, Sleep, sleep disturbance/disorders, sleep problems, smith-magenis-syndrome, Therapy, Trajectory

Tags: 1999, Brain and Development, melatonin, Miyamoto A, Oki J, Okuno A, pharmacologic intervention, Rett syndrome, sleep disturbance/disorders, Takahashi S

Tags: 1998, Budden S S, Developmental Medicine and Child Neurology, McArthur A J, melatonin, pharmacologic intervention, Rett syndrome, sleep disturbance/disorders

Tags: 1995, Alila A, American Journal Of Medical Genetics, body temperature, characteristics, Children, circadian rhythms, cortisol, disturbance, Genetics & Heredity, Hatonen T H, Heikkila E, Heiskala H, Laakso M L, melatonin, mental handicap, Motor Activity, NCL3, neuronal ceroid lipofuscinosis, Radioimmunoassay, retina, Salmi T, Santavuori P, Sleep, sleep disturbance/disorders, Telakivi T, Trajectory

Tags: 0 (Antioxidants), 1999, Adolescent, Adult, Antioxidants/tu [Therapeutic Use], Child, Circadian Rhythm, Dose-Response Relationship, Drug Electrophysiology, Female, Hätönen T, Heiskala H, Humans, JL5DK93RCL (Melatonin), Kirveskari E, Laakso M L, Male, melatonin, Melatonin/tu [Therapeutic Use], Molecular Genetics and Metabolism, NCL3, Neuronal Ceroid-Lipofuscinoses/dt [Drug Therapy], pharmacologic intervention, Sainio K, Santavuori P, sleep disturbance/disorders, Sleep Wake Disorders/th [Therapy]

Tags: 2005, Administration Oral, Adult, Antioxidants/pharmacology/therapeutic use, Child, Child Preschool, Cross-Over Studies, Dose-Response Relationship Drug, Double-Blind Method, Female, Hancock E, Humans, Infant, Journal of Child Neurology, Male, melatonin, Melatonin/pharmacology/therapeutic use, O'Callaghan F, Osborne J P, pharmacologic intervention, sleep disturbance/disorders, Sleep Wake Disorders/drug therapy/etiology, Treatment Outcome, Tuberous Sclerosis, Tuberous Sclerosis/complications

Tags: 0 (Antioxidants), 2005, 2208-40-4 (6-sulfatoxymelatonin), Administration Oral, Adolescent, Antioxidants, Antioxidants/ad [Administration & Dosage], Antioxidants/pk [Pharmacokinetics], Case-Control Studies, characteristics, Child, Child Preschool, Circadian Rhythm, English J, Female, Hancock E, Humans, JL5DK93RCL (Melatonin), Journal of Child Neurology, Male, melatonin, Melatonin/aa [Analogs & Derivatives], Melatonin/ad [Administration & Dosage], Melatonin/pk [Pharmacokinetics], Melatonin/ur [Urine], O'Callaghan F, Osborne J P, Reference Values, sleep disturbance/disorders, Sleep Wake Disorders, Sleep Wake Disorders/co [Complications], Sleep Wake Disorders/pp [Physiopathology], Trajectory, Tuberous Sclerosis, Tuberous Sclerosis/co [Complications], Tuberous Sclerosis/pp [Physiopathology]

Tags: 2012, Adolescent, Allport T, Appleton R, British Medical Journal, Central Nervous System Depressants/administration & dosage/adverse effects, Central Nervous System Diseases/complications, Child, Child Preschool, Child Behavior/drug effects, Choonara I, Developmental Disabilities/complications, Dose-Response Relationship Drug, Drug Monitoring, Edmond A, Family Health, Female, Gamble C, Gringras P, Humans, Jones A P, Male, melatonin, Melatonin/administration & dosage/adverse effects, Montgomery P, pharmacologic intervention, Polysomnography/methods, Q3 conditions, Severity Of Illness Index, sleep disturbance/disorders, Sleep Wake Disorders/diagnosis/drug therapy/etiology, Sleep/drug effects, Sutcliffe A, Treatment Outcome, unspecified Q3 conditions, Whitehouse W P, Wiggs L, Williamson P R

Tags: 2005, Adolescent, Adult, Age of Onset, Archives of Disease in Childhood, Behavior Therapy, Benzodiazepines, characteristics, Child, Child Preschool, Delatycki M B, Fraser J, Gason A A, Humans, Incidence, Infant, Infant Newborn, melatonin, Melatonin/therapeutic use, MPS III, Mucopolysaccharidosis III/psychology, Preschool, Q3 Scoping Review Results, Questionnaires, Sleep Disorders/epidemiology/etiology/therapy, sleep disturbance/disorders, Trajectory, Treatment Outcome, Wraith J E

Tags: 2001, Developmental Disabilities, Dodge N N, Journal of Child Neurology, melatonin, Neurosciences & Neurology, Pediatrics, pharmacologic intervention, sleep disturbance/disorders, unspecified developmental disabilities, Wilson G A

Tags: 2011, De Leersnyder H, Laudon M, melatonin, Pediatric Neurology, pharmacologic intervention, PR melatonin, prolonged-release melatonin, Rett syndrome, sleep disturbance/disorders, Zisapel N

Tags: 1996, Adolescent, Camfield C, Camfield P, Child, Child Preschool, Dooley J, Double-Blind Method, Female, Gordon K, Humans, Intellectual Disability/complications, Journal of Child Neurology, Male, melatonin, Melatonin/therapeutic use, neurodevelopmental disorder, pharmacologic intervention, sleep disturbance/disorders, Sleep Wake Disorders/drug therapy/etiology, undefined neurodevelopmental disorders

Tags: 2008, Adolescent, Adult, Aged, Braam W, Central Nervous System Depressants/adverse effects/therapeutic use, Child, Child Preschool, chromosome 18q deletion, Chronic Disease, Comorbidity, Curfs L, Didden R, Double-Blind Method, Female, Humans, Journal Of Intellectual Disability Research, Male, melatonin, Melatonin/adverse effects/therapeutic use, Mental Retardation/epidemiology/psychology, Middle Aged, MPS III, pharmacologic intervention, Q3 Scoping Review Results, Saliva, sleep disturbance/disorders, Sleep Initiation and Maintenance Disorders/drug therapy/epidemiology/psychology, Smits M, Time Factors, Treatment Outcome

Tags: 2012, Appleton R E, autism spectrum disorders, Barker C, CONTROLLED-TRIAL, exogenous melatonin, Gamble C, Gringras P, handicapped-children, Health Care Sciences & Services, Health Technology Assessment, improves sleep, insomnia, Jones A P, melatonin, Montgomery P, neurodevelopmental disorders, onset, pharmacologic intervention, phase, rett-syndrome, serum melatonin, sleep disturbance/disorders, Sutcliffe A, Syndrome, Wiggs L, Williamson P R, young-adults